Drug therapy for hepatitis B.
Until recently, IFN has been the only available therapy for chronic HBV infection; however, many new and exciting therapeutic strategies have emerged during the last decade. Recent advances in our understanding of the replicative mechanism of HBV and the development of potent nucleoside analogues have opened a new era in the treatment of HBV. Lamivudine has been introduced as an alternative to IFN, showing at least similar efficacy, but with a wider spectrum of indications and without the adverse effects. Therapeutic vaccination and molecular or gene therapy are being investigated as potential approaches, and aggressive combination therapy is emerging as a promising strategy. Based on the experience with HIV, the future of drug therapy against HBV likely includes combination therapy with 1 or more nucleoside/nucleotide analogues and an immune-modulating agent, such as IFN or a therapeutic vaccine. This combination may act synergistically against HBV and delay or prevent the development of drug-resistant mutants.
Regev
A
A
Division of Hepatology, Center for Liver Diseases, University of Miami School of Medicine, Miami, Fla., USA.
Schiff
E R
ER
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000998:Antiviral Agents / Q000008:administration & dosage*; D018450:Disease Progression; D005260:Female; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007372:Interferons / Q000008:administration & dosage; D019259:Lamivudine / Q000008:administration & dosage; D016031:Liver Transplantation; D008297:Male; D063065:Organophosphonates; D011379:Prognosis; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage*
D000998:Antiviral Agents; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; C053001:adefovir; D007372:Interferons; D000225:Adenine